Atypical Guillain–Barre syndrome with T6 sensory level

Osamah AL-Ameen¹, mohanad faisal², salma mustafa², and Mohammed alhatou¹

¹Hamad Medical Corporation ²Hamad medical corportation

July 15, 2022

Abstract

Guillain-Barré syndrome is an acute immune-mediated demyelinating disease. Typical features include progressive ascending lower extremity weakness and areflexia. Several variants have been described which can make the diagnosis challenging. Here, we report a case of GBS presenting with progressive lower limb weakness and T6 sensory level.

Introduction:

Guillain–Barre syndrome (GBS) is an acute immune-mediated inflammatory demyelinating polyneuropathy, and it is the most common cause of acute flaccid paralysis worldwide.

It is occurring with an overall incidence of 1 to 2 cases per 100,000 people per year. The disease's incidence rises by about 20% every decade of age, and males are more likely to contract it than females [1].

It mainly affects most of the spinal nerve roots and peripheral nerves and often involves the cranial nerves and is characterized by symmetrical limb weakness and areflexia [2].

Most patients present with an antecedent illness, most commonly an upper respiratory tract infection or diarrheal illness, before the onset of progressive motor weakness. Several microorganisms have been associated with Guillain-Barré syndrome, most notably Campylobacter jejuni, Zika virus, influenza, Mycoplasma pneumoniae, and cytomegalovirus. and in 2020, the severe acute respiratory syndrome coronavirus [3].

Diagnostic criteria for GBS were originally proposed for research in 1978 by the National Institute of Neurological Disorders and Stroke (NINDS). Including, acute progressive and symmetric muscle weakness with absent or depressed deep tendon reflexes [4].

The weakness can vary from mild difficulty with walking to nearly complete paralysis of all extremities, including facial, respiratory, and bulbar muscles. Symptoms typically progress over days to four weeks. Patients may also have mild sensory symptoms and dysautonomia.

Lumbar puncture for CSF analysis should be performed in all patients to confirm the GBS diagnosis and exclude other sources of the symptoms. With a typical finding of an elevated CSF protein with a normal white blood cell count.

Electrodiagnostic studies consisting of nerve conduction studies (NCS) and electromyography (EMG) are performed in most patients to support the diagnosis of GBS as well as to provide prognostic information regarding the nature and severity of nerve dysfunction.

Multiple variants of GBS have been described. Here we will present a rare case of GBS that presented with lower limb weakness, areflexia, and atypical sensory level.

Case Presentation:

A 61-year-old Indian female with a past medical history of diabetes mellitus and chronic mechanical back pain presented with progressively worsening lower limb weakness, gait difficulty, and reduced sensation in the abdomen and lower limbs. and numbness in her trunk and bilateral lower extremities. She denied urinary or bowel incontinence. There were no abnormal movements or a reduced level of consciousness. Her symptoms were preceded by a febrile watery diarrheal illness 7 days before the onset of these symptoms. However, on presentation, her diarrhea had already subsided. Family and social history were unremarkable. Her vital signs were within the normal range. Physical examination showed intact consciousness, speech, and cranial nerves. Lower limb power was 3/5 proximally and 4/5 distally. Reflexes were 1+ in the upper limb and areflexia in the lower limb. The sensory exam showed loss of sensation in all modalities, including light touch, pain, temperature, joint position, and vibration below the T6 level. Finger to-nose and heel to shin tests were normal, but gait was unsteady.

The initial workup showed leukocytosis (WBC of 12.000) with a normal complete metabolic profile. urgent Magnetic resonance images (MRI) of the whole spine (figure 1) to exclude transverse myelitis or cord compression were inconclusive apart from mild multilevel degenerative changes seen in the mid-cervical, mid-dorsal, and lower lumbar regions, predominantly at the level of C5-C6, C6-C7, T8-T9, L3-L4 and L4-L5. CSF studies showed protein of 1.57 gm/dl with normal cell counts consistent with albumin-cytologic dissociation(Table 1). CSF tests for infection were unremarkable as well, including bacterial and virologic studies. Nerve conduction studies showed absent F-waves of both perineal and tibial nerves, otherwise an unremarkable study. Needle examination revealed positive sharp waves with decreased recruitment in both iliopsoases, consistent with early neurogenic changes. Denervation was also seen in the L1-L2 paraspinal muscles.

In view of her clinical presentation of acute flaccid paralysis with areflexia, unremarkable MRI findings, CSF albumin-cytologic dissociation, and absent lower extremity F-waves, she was diagnosed with having possible GBS and she was started on a 5-day course of intravenous (IV) immunoglobulin with a standard dose of 0.4 gm/kg, which was later followed by a 5-day course of IV pulse methylprednisolone. At first, her lower limb weakness worsened to 1/5 and she developed bowel and bladder dysfunction.

A follow-up MRI of the spine 1 week after the first one did not show any new changes. Over the next 2 to 4 weeks, the patient started to recover gradually, with improvement in her sensations first, then full recovery of motor symptoms with active rehabilitation with the help of an occupational therapist and physiotherapist. On follow-up four months later, she remained independent in all activities of daily living.

Discussion:

GBS manifests itself in a variety of ways, ranging from typical peripheral 4 limb weakness with areflexia to numerous variants that complicate diagnosis and management. Typical GBS usually presents with ascending limb weakness with hyporeflexia/areflexia with minor sensory symptoms and usually involves the 4 upper limbs [4]. Besides the typical presentation of GBS, clinical variants are based on the types of nerve fibers involved (motor, sensory, sensory, and motor, cranial, or autonomic) and the mode of fiber injury (demyelinating vs axonal) [5, 6]. The most common mode of nerve fiber injury is demyelinating, while axonal motor and axonal sensory variants have been described [6] and are associated with rapid progression and poor prognosis [7]. Axonal variants are usually preceded by campylobacter jejune infection [8].

GBS typically has ascending weakness, but descending variants have been described, including the Miller-Fischer variant, which consists of ophthalmoplegia, ataxia, and areflexia [9]. Another cranial variant is the Bickerstaff brainstem encephalitis, which is characterized by alteration in consciousness, hyperreflexia, ataxia, and ophthalmoplegia [10].

A less common paraparetic motor variant affects the legs selectively with areflexia, mimicking an acute spinal cord lesion, and is associated with back pain [11]. In most cases, the paraparetic variant is usually milder compared to the classical GBS, and in 50% of the cases, there are abnormalities in upper limb nerves observed in NCS [12].

While the sensory symptoms in GBS are typically mild, pure sensory variants have been described and are usually characterized clinically by exclusive sensory symptoms and signs that reach their nadir in a maximum of 6 weeks without related systemic disorders and other diseases or conditions [13].

Our case is a 62-year-old lady who presented with progressive ascending lower limb weakness with areflexia in addition to the sensory level of T6. MRI excluded spinal cord compression and demyelination. CSF studies showed albumin-cytological dissociation. NCS showed absent F-waves of both the perineal and tibial nerves. She was given intravenous immunoglobulin followed by five days of IV methylprednisolone, and her symptoms improved over four weeks. Our most likely diagnosis was GBS based on the presentation of acute flaccid paralysis, areflexia, preceding diarrheal illness, CSF studies, and lack of evidence of demyelination and cord compression on MRI, in addition to the duration and course of her illness. We think that our case is like the case reported by Khoo et al. and may represent a new variant of GBS [14]. It is important to note that typical NCS findings are not always present in GBS as it is affected by timing and multiple studies at different times are needed [15].

Another argument is the possibility of transverse myelitis provided that our patient has sensory level and with the onset of symptoms typical of transverse myelitis, but the diagnostic criteria [16] don't apply in our case as there is an absence of demyelination in repeated MRI and no CSF leukocytosis.

Conclusion:

GBS varies in its presentation, and atypical presentation with sensory level may represent a new variant. further studies are needed to confirm our suspicion.

Figures and tables :

Table 1: CSF Analysis

CSF Analysis	CSF Analysis	Normal Values
Appearance	Clear	Clear
Color	Colorless	Colorless
RBC	333 /uL	(0-2)
WBC	8 /uL	(0-5)
CSF Glucose	7.49 mmol/L	(2.22 - 3.89)
CSF Protein	1.57 gm/L	(0.15 - 0.45)
Albumin Cytologic Dissociation	Present	Absent
CSF Culture	Negative	

Figure 1: MRI of the thoracic spine

	Synapse Mobility	x +	EN English (United States)
÷	ightarrow C $ ightarrow$ https://h	mcsnymobility.hmc.org.qa:8443/viewer	A [∧] ∑≞ 😩 …
iQ	Study List	Navigate ■	Overlay
	4:12 tse_sag_384 13 images 5:12 tse_sag_384 13 images	Senes Number: 5 Senes Description: 12; tse_sag_384 Silce Thickness: 3:00 Senes Date: 2021-11-21	RAJARATHINAM SELUT HC0450510 1960-05-08 F 2021-17-21 16 28/09
	6: 12_tse_tra_p2 30 images 20 images 30 images		P JMR SIEMENS
	8: t2_tse_tra_p2 30 images	EthoDum	Magnetic Field Strength: \$ ¹ 60 ibers 0 <mark>, Ech</mark> o Time: 75.00, Echo Train Length: 19, Filp A 384:X84 Window/Level: 1020/486
	9: 12_tse_tra_p2 25 images	↓ =	
[←]			
		o # 💽 🛤 🛱 🕼 🜌 🖸 🔞	🥚 39*C Sunny ヘ ট 📭 句) 🦟 255 PM

References:

1. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012;366(24):2294-304. doi: 10.1056/NEJM-ra1114525. PubMed PMID: 22694000.

2. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol. 1978;3(6):565-6. doi: 10.1002/ana.410030628. PubMed PMID: 677829.

3. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214-28. Epub 20210226. doi: 10.1016/s0140-6736(21)00517-1. PubMed PMID: 33647239.

4. Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31(2):491-510. Epub 20130219. doi: 10.1016/j.ncl.2013.01.005. PubMed PMID: 23642721; PubMed Central PMCID: PMC3939842.

5. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain. 1986;109 (Pt 6):1115-26. doi: 10.1093/brain/109.6.1115. PubMed PMID: 3790970.

6. Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol. 1996;39(1):17-28. doi: 10.1002/ana.410390105. PubMed PMID: 8572662.

7. Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes. Neurology. 2003;61(4):471-4. doi: 10.1212/01.wnl.0000081231.08914.a1. PubMed PMID: 12939419.

8. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118 (Pt 3):597-605. doi: 10.1093/brain/118.3.597. PubMed PMID: 7600081.

9. FISHER M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57-65. doi: 10.1056/NEJM195607122550201. PubMed PMID: 13334797.

10. BICKERSTAFF ER, CLOAKE PC. Mesencephalitis and rhombencephalitis. Br Med J. 1951;2(4723):77-81. doi: 10.1136/bmj.2.4723.77. PubMed PMID: 14848512; PubMed Central PMCID: PMC2069534.

11. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol. 1986;43(11):1150-2. doi: 10.1001/archneur.1986.00520110044012. PubMed PMID: 2946281.

12. van den Berg B, Fokke C, Drenthen J, van Doorn PA, Jacobs BC. Paraparetic Guillain-Barré syndrome. Neurology. 2014;82(22):1984-9. Epub 20140507. doi: 10.1212/WNL.000000000000481. PubMed PMID: 24808021.

13. Uncini A, Yuki N. Sensory Guillain-Barré syndrome and related disorders: an attempt at systematization. Muscle Nerve. 2012;45(4):464-70. doi: 10.1002/mus.22298. PubMed PMID: 22431077.

14. Khoo CS, Ali AH, Remli R, Tan HJ. A case of Guillain-Barré syndrome (GBS) presenting with acute urinary retention and T6 sensory level. Clin Med (Lond). 2018;18(4):308-10. doi: 10.7861/clinmedicine.18-4-308. PubMed PMID: 30072555; PubMed Central PMCID: PMC6334053.

15. Rath J, Schober B, Zulehner G, Grisold A, Krenn M, Cetin H, et al. Nerve conduction studies in Guillain-Barré syndrome: Influence of timing and value of repeated measurements. J Neurol Sci. 2021;420:117267. Epub 20201213. doi: 10.1016/j.jns.2020.117267. PubMed PMID: 33352506.

16. Group TMCW. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499-505. doi: 10.1212/wnl.59.4.499. PubMed PMID: 12236201.

Acknowledgment:

Open access article was funded by Qatar National library

Availability of data:

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflict of interest:

The authors have no conflict of interest to declare.